ARWR
Arrowhead Pharmaceuticals, Inc.
September 16, 2026 · intraday
- Rarity
- 1.74
- Peak move
- −8.39%
- Float cap
- $8.8B
Arrowhead Pharmaceuticals develops RNA interference (RNAi) therapeutics for diseases with a genetic basis. Its first approved product, REDEMPLO (plozasiran), treats familial chylomicronemia syndrome, and the company has a pipeline targeting severe hypertriglyceridemia and other conditions. It also licenses its technology to pharmaceutical partners.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
6 events · 0 from SEC or newswire · 0 timed with the move- Key event
executive_remarkArrowhead CEO Chris Anzalone said at the H.C. Wainwright conference that REDEMPLO's launch is a 'slow burn' rather than a gangbusters start, guiding to $3 billion-$4 billion US peak sales and a planned supplemental filing in severe hypertriglyceridemia by year-end.
analyst_ratingJ.P. Morgan analyst Brian Cheng reiterated a Buy rating on Arrowhead Pharmaceuticals, dated September 2026 around the ARO-DIMER-PA interim data, maintaining a bullish stance on the DIMER platform.
retail_flowRetail sentiment on Arrowhead Pharmaceuticals shifted from 'bearish' to 'bullish' on Stocktwits over the 24 hours to September 15, 2026, with message volume rising from 'normal' to 'high' as shares fell more than 10% on the ARO-DIMER-PA data.
- Key event
insider_saleTwo Arrowhead Pharmaceuticals directors sold shares worth a combined approximately $1.19 million, including Adeoye Olukotun's 2,000 shares at $86.96 and Michael Perry's 11,600 shares at $87.30, in transactions dated August 18, 2026.
- Key event
clinical_readoutArrowhead Pharmaceuticals reported interim topline Phase 1/2a data for ARO-DIMER-PA, its dual-functional RNAi therapeutic targeting PCSK9 and APOC3 in mixed hyperlipidemia, showing mean maximal single-dose reductions in serum PCSK9 of 72% and APOC3 of 88%, with LDL-C down 54%, triglycerides down 73%, non-HDL cholesterol down 61% and ApoB down 50%, and dose escalation through 400 mg with no drug-related SAEs.
investor_dayArrowhead CEO Chris Anzalone and CMO James Hamilton presented at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, discussing ARO-DIMER-PA data, the plozasiran launch and the broader RNAi pipeline.